QNTM Stock — Quantum BioPharma Ltd.

Quantum BioPharma Ltd. (QNTM)

Updated October 16, 2026.

QNTM is a Stock. Its deepest 1-year drawdown was 86.1%.

Quantum BioPharma Ltd. is a biopharmaceutical company developing drug candidates for neurodegenerative, inflammatory, and metabolic disorders, along with treatments for alcohol misuse; its lead program, Lucid-MS, is in Phase 2 clinical trials for multiple sclerosis, while the company also maintains a portfolio of strategic investments in residential property loans. The company does not currently distribute to shareholders. This security appeals to investors seeking exposure to early-stage drug development with potential for significant upside if clinical trials succeed, though it carries the substantial risks inherent in biotech development.

QNTM performance

Returns are updating. QNTM's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 86.1%.

QNTM key facts

Asset type

Stock

Asset class

Equity

Inception date

06/08/2018

Distribution frequency

None

Last close

$2.47 (as of 2026-10-16)

Market cap

$15,880,996

Average volume

190412.0

Beta

0.384

Payout ratio

0.0%

EPS

$-4.68

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

QNTM risks and drawbacks

The deepest 1-year drawdown on record here is 86.1%.

Who may consider QNTM — and who may not

It is a weaker fit for investors who need monthly cash flow (QNTM does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on QNTM

• All tickers starting with Q

Tagged: Healthcare.

Frequently asked questions